Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

In fall 2025, Summers County Comprehensive High School athlete Avery Lilly will be trading in her orange and black gear for ...